Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): Three‐month interim analysis results

BACKGROUND: Direct oral anticoagulants are the first‐line drugs for anticoagulation therapy in nonvalvular atrial fibrillation (NVAF). However, a real‐world, large‐scale, clinical study on edoxaban has not been performed. Our ongoing postmarketing surveillance, ETNA‐AF‐Japan (Edoxaban Treatment in r...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamashita, Takeshi, Koretsune, Yukihiro, Ishikawa, Mayumi, Shiosakai, Kazuhito, Kogure, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373660/
https://www.ncbi.nlm.nih.gov/pubmed/30805052
http://dx.doi.org/10.1002/joa3.12149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373660/
https://www.ncbi.nlm.nih.gov/pubmed/30805052
http://dx.doi.org/10.1002/joa3.12149

Ejemplares similares